Abemaciclib for HR+/HER2- advanced or metastatic breast cancer

PALMARES-2: comparing first-line palbociclib, ribociclib, or abemaciclib in HR+/HER2- aBCПодробнее

SABCS 2023 Breast Cancer Highlights – NATALEE, MONARCH-3, INAVO120, TROPION-Breast01Подробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

#abemaciclib | Uses, Dosage, Side Effects & Mechanism | VerzenioПодробнее

2023 Updates In Metastatic Breast Cancer TreatmentПодробнее

First-line camizestrant for ER+/HER2- advanced breast cancerПодробнее

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim dataПодробнее

Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancerПодробнее

monarcHER: final OS results of abemaciclib in HR+, HER+ breast cancerПодробнее

Metastatic breast cancer at ESMO 2022: TROPiCS02, MONARCH 3 and SYNERGYПодробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

Continuous Abemaciclib Treatment Leads to Breast Cancer Inhibition | OncotargetПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...Подробнее

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancerПодробнее

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancerПодробнее

Report Back From ASCO on Metastatic Breast CancerПодробнее

A 2D animation explainer video for Abemaciclib - #WebdewPortfolioПодробнее

Findings With Abemaciclib Plus Tamoxifen in Advanced Breast CancerПодробнее